Myocardial Infarction Market Size, Share Global Analysis Report, 2024 – 2032

Industry Insights

[215+ Pages Report] According to Facts & Factors, the global myocardial infarction market size was worth around USD 2,091.28 million in 2023 and is predicted to grow to around USD 3,812.52 million by 2032 with a compound annual growth rate (CAGR) of roughly 6.90% between 2024 and 2032.

To know more about this report | Request Free Sample Copy

Market Overview

Myocardial infarction is more commonly known as a heart attack. It is a serious medical condition in which the muscles of the heart start dying due to a lack of sufficient blood flow. Myocardial infarction is mainly caused due to blockage in the arteries that are responsible for supplying blood to the heart. In case, the blood flow is not restored as soon as possible, there is a high risk of fatality or some form of permanent heart damage. The reasons for lack of blood flow supply to the heart are several however, the most common is related to blockages in the arteries. Myocardial infarction is a life-threatening medical condition that requires urgent care.

As per statistics submitted by the Cleveland Clinic, more than 800,000 people in the US suffer from a heart attack every year with coronary heart disease being the most common reason for deaths in the country. The primary symptoms of a heart attack include trouble breathing, chest pain, stomach discomfort, insomnia, anxiety, and passing out or feeling dizzy. The heart attack blockage is caused by the build-up of atherosclerosis which results in coronary heart disease. However, other reasons that can lead to heart attack are eating disorders, trauma, rare medical conditions, coronary artery spasms, and anomalous coronary arteries. The demand for myocardial infarction treatment is projected to grow during the forecast period due to several supporting factors.

Key Insights:

• As per the analysis shared by our research analyst, the global myocardial infarction market is estimated to grow annually at a CAGR of around 6.90% over the forecast period (2024-2032)
• In terms of revenue, the global myocardial infarction market size was valued at around USD 2,091.28 million in 2023 and is projected to reach USD 3,812.52 million, by 2032.
• The myocardial infarction market is projected to grow at a significant rate due to the increasing patient rate of heart attacks
• Based on the care providers, the hospital segment is growing at a high rate and will continue to dominate the global market as per industry projection
• Based on the drug class, the analgesics segment is anticipated to command the largest market share
• Based on region, North America is projected to dominate the global market during the forecast period

To know more about this report | Request Free Sample Copy

Growth Drivers

• Increasing patient rates with heart attacks will lead to higher market demand

The global myocardial infarction market is expected to grow due to the rising number of patients with myocardial infarction. While the condition was earlier reported to be more common in women over 55 years and men over 45 years, the condition can occur across age and gender. Several recent incidents of young children suffering from fatal myocardial infarction have been reported worldwide. Over 1 million people globally are affected by the condition every year as per official reports. Myocardial infarction has several associated lifestyle causes.

For instance, the condition is more commonly observed in people with obesity. In addition to this, frequent exposure to stress and alcohol abuse increases the risk of a heart attack. Diabetic patients and people with high cholesterol levels are also more prone to heart attacks. Diabetes, for instance, is one of the most prevalent medical conditions impacting nearly 422 million people as per the World Health Organization. With the changing lifestyle of the population along with the growing number of elderly people, myocardial infarctions may become more common in the coming years resulting in higher demand for treatment processes.

• Growing initiatives by governments and healthcare agencies to create patient awareness may promote higher revenue

Since heart attacks can be fatal in the absence of urgent medical care, governments along with healthcare agencies globally are investing in developing and conducting patient awareness programs. These initiatives are aimed at imparting essential information about heart attacks, their causes, and the response in case of encountering an incident related to heart attacks thus promoting growth in the global myocardial infarction market. For instance, the US runs The Heart Truth nationwide initiative that focuses on generating awareness about heart-related conditions and promotes living a healthy lifestyle.

Restraints

• High cost of treatment will limit the market’s growth trajectory

The global industry for myocardial infarction is projected to be limited due to the higher cost of treating heart attacks. In some cases, patients may require extensive heart surgery which can be expensive in the absence of insurance or an appropriate medical reimbursement plan. In addition to this, post-operative care is extremely long and the patient may have to prescribe expensive medicines thus limiting treatment accessibility, especially among people with limited financial assistance. In 2020, the average cost of bypass surgery in the US was around USD 29,000 to $210,000.

Opportunities

• Ongoing investments in improving diagnostic and treatment processes for heart attacks may generate extensive growth opportunities

The global myocardial infarction industry is projected to generate growth opportunities due to the increase in investments in improving heart attack diagnosis and treatment. In May 2023, researchers at the University of Edinburgh developed a new Artificial Intelligence (AI) powered algorithm called the CoDE-ACS that can be used for diagnosing heart attacks with utmost precision and in limited time. The developers claimed that the tool has successfully managed to rule out myocardial infarctions in more than twice the number of patients tested by current methods and with an accuracy rate of 99.6%.

Similarly, the American Heart Association has claimed that AI could be leveraged to improve diagnostic measures associated with heart attacks in the future. In April 2024, UC David Health was conducting a new clinical trial for the evaluation of a breakthrough technology for assessing adult patients for the condition called non-obstructive Coronary Artery Disease (CAD) in the cardiology clinic and emergency department. The system has been developed by Acarix and it is a point-of-care diagnostic technology.

The industry for heart attack treatment has witnessed development in terms of the identification of new biomarkers that could be helpful in the early detection of acute myocardial infarction (AMI) along with other therapeutic developments such as supersaturated oxygen (SSO2) therapy, hypothermia therapy, and targeted anti-inflammatory therapy along with stem cell therapy and targeted angiogenesis therapy could help the industry flourish.

Challenges

• Lack of sufficient infrastructure catering to the economically suffering patient segments may challenge the market expansion rate

The global myocardial infarction market is expected to be challenged by the lack of sufficient healthcare infrastructure in developing and economically poor countries. As per WHO, around 4.5 billion people worldwide do not have 100% access to medical facilities provided by essential health services. Additionally, service providers may not be equipped with advanced myocardial infarction diagnostic and treatment tools thus limiting the quality of the service provided.

Segmentation Analysis

The global myocardial infarction market is segmented based on distribution channel, administration route, drug class, and region.

Based on the care providers, the global market segments are hospitals, ambulatory service providers, and specialty clinics. In 2023, the highest growth was witnessed in the hospital segment driven by the higher patient rate observed in these hospital facilities. The rise in the number of government-owned and affordable hospitals is fueling the market demand rate. In addition to this, global healthcare investments are on the rise since patient care demand has surged in the last decade. As per the American Hospital Association, the US has around 6120 hospitals.

Based on the administration route, the myocardial infarction industry  divisions are injectable and oral.

Based on the drug class, the global market divisions are antithrombotic agents, antiplatelet agents, beta-adrenergic blockers, glycoprotein IIb/IIIa inhibitors, angiotensin-receptor blockers, angiotensin-converting enzyme (ACE inhibitors, and analgesics. In 2023, the highest revenue was generated in the analgesics segment and it is expected to dominate the largest share of the myocardial infarction industry during the projection period.

An analgesic is a medication used for treating pain by targeting the central and peripheral nervous system. The most common analgesics are called Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). In 2024, the global NSAIDs market is expected to generate an overall revenue of over USD 20 billion.

Report Scope

Report Attribute	Details
Market Size in 2023	USD 2,091.28 Million
Projected Market Size in 2032	USD 3,812.52 Million
CAGR Growth Rate	6.90% CAGR
Base Year	2023
Forecast Years	2024-2032
Key Market Players	Abbott Laboratories, Johnson & Johnson, GlaxoSmithKline PLC, AstraZeneca PLC, Roche Holding AG, Bristol-Myers Squibb Company, Novartis AG, Boehringer Ingelheim, Eli Lilly and Company, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc, Amgen Inc., Sanofi S.A., Bayer AG., and Others.
Key Segment	By Care Providers, By Administration Route, By Drug Class, and By Region
Major Regions Covered	North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa
Purchase Options	Request customized purchase options to meet your research needs. Explore purchase options

Regional Analysis

• North America to dominate the industry during the projection period

The global myocardial infarction market will be dominated by North America during the projection period. One of the preliminary reasons for the higher regional market growth rate is the existence of a highly evolved and comprehensive medical infrastructure in the US and Canada. The former is one of the world’s leading contributors to the global healthcare sector in terms of advanced diagnostic devices and treatment processes. The US-based agencies specializing in research & development related to several medical conditions are highly popular in the international market.

In addition to this, undertaking and awareness related to myocardial infarction is widely prevalent in the US due to the higher number of heart attack patients in the country. The surging investments toward the development of novel myocardial infarction diagnostic and treatment solutions will help the industry achieve significant growth during the projection period.

In October 2023, the Canadian Cardiovascular Society (CCS) issued the first-ever classification of heart attacks based on tissue damage. These classifications will help the medical community bring changes to the treatment protocols and change treatment guidelines.

Competitive Analysis

The global myocardial infarction market is led by players like:

• Abbott Laboratories
• Johnson & Johnson
• GlaxoSmithKline PLC
• AstraZeneca PLC
• Roche Holding AG
• Bristol-Myers Squibb Company
• Novartis AG
• Boehringer Ingelheim
• Eli Lilly and Company
• Merck & Co. Inc.
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc
• Amgen Inc.
• Sanofi S.A.
• Bayer AG.

The global myocardial infarction market is segmented as follows:

By Care Providers Segment Analysis

• Hospitals
• Ambulatory Service Providers
• Specialty Clinics

By Administration Rout Segment Analysis

• Injectable
• Oral

By Drug Class Segment Analysis

• Antithrombotic Agents
• Antiplatelet Agents
• Beta-adrenergic Blockers
• Glycoprotein IIb/IIIa Inhibitors
• Angiotensin-receptor Blockers
• Angiotensin-converting Enzyme (ACE) Inhibitors
• Analgesics

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America